These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30672808)

  • 1. From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants.
    Rhainds D; Tardif JC
    Curr Opin Lipidol; 2019 Apr; 30(2):101-107. PubMed ID: 30672808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels.
    Villard EF; EI Khoury P; Frisdal E; Bruckert E; Clement K; Bonnefont-Rousselot D; Bittar R; Le Goff W; Guerin M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):822-8. PubMed ID: 23372063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity.
    Koekemoer AL; Codd V; Masca NGD; Nelson CP; Musameh MD; Kaess BM; Hengstenberg C; Rader DJ; Samani NJ
    Arterioscler Thromb Vasc Biol; 2017 Oct; 37(10):1956-1962. PubMed ID: 28860221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Endothelial Lipase on Cholesterol Efflux Capacity of Serum and High-density Lipoprotein.
    Schilcher I; Kern S; Hrzenjak A; Eichmann TO; Stojakovic T; Scharnagl H; Duta-Mare M; Kratky D; Marsche G; Frank S
    Sci Rep; 2017 Oct; 7(1):12485. PubMed ID: 28970555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
    Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of cholesterol efflux capacity in patients with myocardial infarction.
    Silvain J; Kerneis M; Guerin M; Montalescot G
    Curr Opin Cardiol; 2019 Nov; 34(6):714-720. PubMed ID: 31464772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation, remodeling, and other factors affecting HDL cholesterol efflux.
    Ronsein GE; Vaisar T
    Curr Opin Lipidol; 2017 Feb; 28(1):52-59. PubMed ID: 27906712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
    Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
    J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.
    Rohatgi A
    Prog Cardiovasc Dis; 2015; 58(1):32-40. PubMed ID: 25968932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
    Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
    Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis.
    Fadaei R; Poustchi H; Meshkani R; Moradi N; Golmohammadi T; Merat S
    Sci Rep; 2018 Aug; 8(1):11691. PubMed ID: 30076407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of HDL Cholesterol Efflux Capacity after Virgin Olive Oil Ingestion: Interrelationships with Fluidity of HDL Monolayer.
    Fernández-Castillejo S; Rubió L; Hernáez Á; Catalán Ú; Pedret A; Valls RM; Mosele JI; Covas MI; Remaley AT; Castañer O; Motilva MJ; Solá R
    Mol Nutr Food Res; 2017 Dec; 61(12):. PubMed ID: 28887843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDL and Reverse Cholesterol Transport Biomarkers.
    Riggs KA; Rohatgi A
    Methodist Debakey Cardiovasc J; 2019; 15(1):39-46. PubMed ID: 31049148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variants at the APOE /C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High-Density Lipoprotein Cholesterol.
    Low-Kam C; Rhainds D; Lo KS; Barhdadi A; Boulé M; Alem S; Pedneault-Gagnon V; Rhéaume E; Dubé MP; Busseuil D; Hegele RA; Lettre G; Tardif JC
    J Am Heart Assoc; 2018 Aug; 7(16):e009545. PubMed ID: 30369316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis.
    Salahuddin T; Natarajan B; Playford MP; Joshi AA; Teague H; Masmoudi Y; Selwaness M; Chen MY; Bluemke DA; Mehta NN
    Eur Heart J; 2015 Oct; 36(39):2662-5. PubMed ID: 26188212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability, and telomere length in healthy octogenarians.
    Zimetti F; Freitas WM; Campos AM; Daher M; Adorni MP; Bernini F; Sposito AC; Zanotti I
    J Lipid Res; 2018 Apr; 59(4):714-721. PubMed ID: 29436385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause.
    El Khoudary SR; Hutchins PM; Matthews KA; Brooks MM; Orchard TJ; Ronsein GE; Heinecke JW
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3419-28. PubMed ID: 27399353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis.
    Favari E; Thomas MJ; Sorci-Thomas MG
    J Cardiovasc Pharmacol; 2018 Jun; 71(6):325-331. PubMed ID: 29528874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-Density Lipoprotein Functionality in Metabolic Syndrome.
    Khan AA; Mundra PA; Straznicky NE; Nestel PJ; Wong G; Tan R; Huynh K; Ng TW; Mellett NA; Weir JM; Barlow CK; Alshehry ZH; Lambert GW; Kingwell BA; Meikle PJ
    Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):438-447. PubMed ID: 29284607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.